Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Regulatory approval: thyroid eye disease

June 29, 2026

FDA has approved Viridian Therapeutics’ Lumvoa (veligrotug-vvze) for thyroid eye disease (TED), giving the company a new branded option for both chronic and active phases of the disorder. The...

AI drug discovery: neuroimmune collaboration economics

June 29, 2026

Insilico Medicine and SK Biopharmaceuticals have launched a neuroimmune AI drug collaboration that could generate up to $2.5 billion for Insilico. The partners say the program will use Insilico’s...

Drug manufacturing innovation: cell-free system cost reduction

June 29, 2026

A research team led by Joongoo Lee at POSTECH (Pohang University of Science and Technology) reported a cost-cutting breakthrough for reconstituted cell-free systems, reporting a 95% reduction in...

Clinical/epidemiology: menstrual cycle effects on vaccine outcomes

June 29, 2026

New research in npj Women’s Health reports that timing COVID-19 vaccination within the menstrual cycle is associated with differences in reported side effects. Using menstrual-cycle data from a...

Cancer biology: neural activity and tumor progression

June 29, 2026

Harvard-based cancer neuroscientist Humsa Venkatesh described how work on neural-tumor interactions has expanded beyond gliomas toward broader cancer types. Her earlier findings centered on...

Cardiac monitoring: deep-learning ECG biomarker for sudden death risk

June 29, 2026

A new report claims discovery of an ECG biomarker for sudden cardiac death using deep learning. The item describes a computational approach that identifies a signal pattern from ECG data intended...

Regulatory and corporate oversight: NIH grant whistleblower case

June 29, 2026

A federal judge allowed most of a whistleblower lawsuit against Harvard to proceed, advancing claims tied to alleged misuse of NIH grant funding by Harvard and a Harvard Catalyst principal...

Medicare policy pressure: Medicare Advantage star rating recalculation

June 29, 2026

CMS has recalculated some 2026 Medicare Advantage Star Ratings after a court ruling found an improper calculation for Clover Health’s rating. The change could boost payments for a limited number...

Funding and partnerships via innovation event coverage (neuro/BCI attention)

June 29, 2026

Coverage highlighted that brain-computer interface (BCI) technology has progressed from decades of clinical research and repeated setbacks to a more tangible near-term application phase. The...

Platform instrumentation: bispecific antibody pipeline (catalog-style item)

June 29, 2026

A catalog-style entry titled “Approved Bispecific Antibodies” points to the growing set of bispecific antibody approvals in the market. While the provided content does not include specific...

Thyroid eye disease drug approvals

June 28, 2026

FDA has cleared Viridian Therapeutics’ thyroid eye disease (TED) therapy Lumvoa (veligrotug-vvze), giving the company an entry point to a market long dominated by Amgen’s Tepezza...

Inflammatory drug safety withdrawals in Europe and the US

June 28, 2026

The European Medicines Agency has moved toward withdrawing marketing authorization for Amgen and Vifor’s inflammatory drug Tavneos, concluding that benefits no longer outweigh risks. The CHMP...

CMS Medicare Advantage payment recalculations

June 28, 2026

CMS is recalculating select 2026 Medicare Advantage Star Ratings after a court ruled that the original calculation for Clover Health’s rating was improperly determined. The change could boost...

AI drug discovery partnership funding scale

June 28, 2026

Insilico Medicine and SK Biopharmaceuticals have launched a neuroimmune AI drug discovery collaboration that could generate up to $2.5 billion in value. The partnership assigns Insilico’s...

Progression-stage MS drug development signal

June 28, 2026

Immunic is advancing its Nurr1 program beyond multiple sclerosis’s inflammation ceiling, with Phase III activity expected to evaluate vidofludimus calcium. The development plan centers on whether...

FDA advisory committee agenda risks and independence scrutiny

June 28, 2026

Upcoming FDA advisory committee meetings are expected to revisit post-independence governance questions, with specific attention on meetings involving Replimune and Capricor. Coverage also notes...

Cell-free protein manufacturing cost breakthrough

June 28, 2026

A research team led by POSTECH (Pohang University of Science and Technology) reported a modular, automated approach to assembling reconstituted cell-free systems and said it reduced the cost of...

Bridging lab and market via genetic code expansion

June 28, 2026

A perspective argues that genetic code expansion (GCE) paired with machine learning can close the lab-to-market gap for engineered proteins and peptides by enabling non-canonical amino acid...

Neurotechnology coverage on BCI innovation

June 28, 2026

BioWorld reports that brain-computer interface (BCI) systems have advanced enough to prompt renewed attention from investors and clinicians after decades of research and setbacks. The coverage...

US drug pricing and access policy pressure around GLP-1 coverage

June 28, 2026

A policy analysis says Medicare’s GLP-1 coverage expansion for seniors requires a more holistic approach to weight management to avoid downstream risk. The piece frames the policy shift as...